LncRNA DLGAP1-AS2 overexpression associates with gastric tumorigenesis: a promising diagnostic and therapeutic target

Abstract

Background: Aberrant expression of long noncoding RNAs (lncRNAs) is associated with the progression of human cancers, including gastric cancer (GC). The function of lncRNA DLGAP1-AS2, as an oncogene, has been identi ed in glioma, hepatocellular carcinoma, and cholangiocarcinoma but not in other malignancies. Therefore, this study was aimed to explore the association of DLGAP1-AS2 with gastric tumorigenesis and beyond.Methods and Results: The expression level of DLGAP1-AS2 was prevaluated in GC datasets from Gene Expression Omnibus (GEO). Moreover, qRT-PCR experiment was performed on 25 paired GC and adjacent normal tissue samples. The Cancer Genome Atlas (TCGA) data were also analyzed for further validations. Consistent with data obtained from GEO datasets, qRT-PCR results revealed that DLGAP1-AS2 was signi cantly (p < 0.0032) upregulated in GC specimens compared to normal samples, which was additionally con rmed using TCGA analysis (p<0.0001). DLGAP1-AS2 expression level was also correlated with age (p =0.0008), lymphatic and vascular invasion (p =0.0415) in internal samples. Also, a signi cant correlation was found between DLGAP1-AS2 and YAP1 expression, as its valid downstream target, in GC samples. Besides, analysis of other prevalent tumor entities using TCGA illustrated the signi cant overexpression of DLGAP1-AS2 in lung, colorectal, and prostate cancers, further indicating its promise as an oncogene. Moreover, ROC curve analysis showed the high accuracy of the DLGAP1-AS2 expression pattern as a diagnostic biomarker for gastric and colorectal cancers. Conclusion: Our ndings indicated that DLGAP1-AS2 might display oncogenic property in gastric tumorigenesis and be suggested as a therapeutic and diagnostic target.

Downregulation of long noncoding RNA B4GALT1-AS1 is associated with Breast Cancer development

“…Many studies have shown that lncRNAs have an important function in biology of cancers and are out of regulation in various cancers [11,25]. It has been shown that the expression of certain lncRNAs is involved in the development and progression of BC, highlighting the different expression patterns of lncRNAs in BC tissues compared to normal breast samples [26,27].…”

“…Studies indicate that lncRNAs participate in metastasis, tumorigenesis and progression of various cancers including BC. While some lncRNAs can act as tumor-enhancing agents, others provide a role as tumor inhibitors [9][10][11]. Some lncRNAs, such as MALAT1 and HOTAIR, are expressed through breast tumorigenesis, showing oncogenic properties; whereas others like GAS5 and XIST function as tumor suppressors [12].…”

Interaction of noncoding RNAs with hippo signaling pathway in cancer cells and cancer stem cells

“…ncRNAs play vital regulatory roles in developing and increasing tumorigenesis by interacting with different signaling pathways, and contain more than 80 % of the genomic content. The lack of interaction of ncRNAs with signaling networks may result in some diseases, such as cancer [ [48] , [49] , [50] , [51] ]. In addition, ncRNAs are able to induce [ 8 ] or inhibit tumorigenesis through the Hippo pathway in Refs.…”